Drug Database · Clinicians

Brimonidine + Timolol

Brands (10) Alphadin Plus, Brilol Plus, Brimochek-T…Show all

Adrenergic agonist (alpha 2 selective)/ beta adrenoreceptor blocker; Combination of sympathomimetic and beta blocking agent in glaucoma therapy; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug10 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID feaf1480-a4b8-4486-992a-96be3a596243, version date March 17, 2026 (COMBIGAN · Allergan, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • COMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE COMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day.

COMBIGAN is a combination of brimonidine tartrate, an alpha-adrenergic receptor agonist, and timolol maleate, a beta-adrenergic receptor inhibitor, indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day.

(1)

Contraindications

4 CONTRAINDICATIONS Bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease. (4.1, 5.1, 5.3) Sinus bradycardia, atrioventricular block, overt cardiac failure, cardiogenic shock. (4.2, 5.2) Neonates and infants (pediatric patients younger than 2 years old). (4.3) Hypersensitivity to any component of this product.

(4.4) 4.1 Reactive Airway Disease I ncluding Asthma, COPD COMBIGAN is contraindicated in patients with reactive airway disease including bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see Warnings and Precautions (5.1, 5.3)]. 4.2 Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock COMBIGAN is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure [see Warnings and Precautions (5.2)]; cardiogenic shock. 4.3 Neonates and Infants (Pediatric Patients Younger than 2 Years Old) COMBIGAN is contraindicated in neonates and infants (pediatric patients younger than 2 years old) [see Use in Specific Populations (8.4)]. 4.4 Hypersensitivity Reactions Local hypersensitivity reactions have occurred following the use of different components of COMBIGAN. COMBIGAN is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) twice daily approximately 12 hours apart. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. One drop in the affected eye(s), twice daily approximately 12 hours apart. (2)

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Patients with Renal Impairment COMBIGAN has not been studied in patients with renal impairment. A study of patients with renal failure showed that timolol was not readily removed by dialysis. The effect of dialysis on brimonidine pharmacokinetics in patients with renal failure is not known. Following oral administration of timolol maleate, the plasma half-life of timolol is essentially unchanged in patients with moderate renal insufficiency.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use COMBIGAN is contraindicated in pediatric patients younger than 2 years old [see Contraindications (4.3)]. During post-marketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine.

The safety and effectiveness of COMBIGAN for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP have been established in pediatric patients aged 2 years and older. Use of COMBIGAN for this indication is supported by evidence from adequate and well-controlled studies of COMBIGAN in adults with additional data from a study of the concomitant use of brimonidine tartrate ophthalmic solution 0.2% and timolol maleate ophthalmic solution in pediatric glaucoma patients (ages 2 to 7 years).

In this well-controlled clinical study, brimonidine tartrate ophthalmic solution 0.2% was dosed three times a day as adjunctive therapy to beta-blockers. The most commonly observed adverse reactions were somnolence (50% to 83% in patients 2 to 6 years) and decreased alertness. In pediatric patients 7 years of age or older (>20 kg), somnolence appears to occur less frequently (25%).

Approximately 16% of patients on brimonidine tartrate ophthalmic solution discontinued from the study due to somnolence.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Dosage forms

Philippines

  • Per ml ophthalmic solution: 2 mg/5 mg
  • Per ml sterile ophthalmic solution: 2 mg/5 mg

Registered products in the Philippines

10 products registered with the Food and Drug Administration (FDA) Philippines list Brimonidine + Timolol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products10
Philippine FDA-registered products for Brimonidine + Timolol
Package insert
Alphadin PlusBrimonidine tartrate + Timolol (as maleate)
2 mg/5 mg per mL Ophthalmic Solution (Eye Drops)White LDPE plastic bottle with nozzle and HDPE cap in 5 mL (net content) (Box of 1's)
Rx
Indoco Remedies LimitedIndia
Medchoice Vision Care Inc.Importer: Ambica International Corporation
DRP-7258-03
Jul 7, 2032
Brilol PlusBrimonidine tartrate + Timolol (as maleate)
2 mg/5 mg per mL Ophthalmic Solution (Eye Drops)White LDPE plastic bottle with nozzle and HDPE cap in 5 mL (net content) Box of 1’s
Rx
Indoco Remedies LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-7258-02
Jul 7, 2027
Brimochek-TBrimonidine tartrate + Timolol (as maleate)
2 mg/5 mg per mL Ophthalmic Solution (Eye Drops)White LDPE plastic bottle x 5mL, with nozzle and HDPE cap [Box of 1's]
Rx
Indoco Remedies LimitedIndia
Ophthamed Pharma Corp.Importer: Ambica International Corporation
DRP-7258
Jul 7, 2027
BrimoTimBrimonidine Tartrate + Timolol Maleate
2 mg/5 mg per mL (0.2%/0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL (Box of 1’s)
Rx
Makcur Laboratories Ltd.India
Ensight Pharmaceuticals IncTrader: Entod Pharmaceuticals Ltd.
DR-XY49728
May 20, 2031
BritelixBrimonidine tartrate + Timolol (as maleate)
2 mg/5 mg per mL (0.2%/0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL (net content) opaque white plastic bottle with nozzle and cap (Box of 1 bottle)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-17701-01
Feb 19, 2031
Bromitol-TBrimonidine tartrate + Timolol (as maleate)
2 mg/5 mg per mL (0.2%/0.5% w/v) Ophthalmic Solution (Eye Drops)
Rx
Makcur Laboratories LimitedIndia
Afree Pharmaceutical Distribution Corporation
DRP-17701
Feb 19, 2031
BrytimBrimonidine Tartrate + Timolol (as maleate)
2mg / 5 mg per mL (0.2%/0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle with PE Nozzle and PVC Cap in 5 mL (net content) (Box of 1's)
Rx
Remington Pharmaceutical Industries (Pvt.) Ltd.Pakistan
Ophthamed Pharma Corp.
DR-XY46247
Feb 7, 2030
CombiganBrimonidine tartrate + Timolol maleate
2 mg/5 mg per mL Ophthalmic Solution (Eye Drops)Plastic Bottle 5mL (Box of 1's)
Rx
Allergan Pharmaceuticals IrelandIreland
Zuellig Pharma Corporation
DR-XY34369
Mar 12, 2028
Isupres PlusBrimonidine tartrate + Timolol (as maleate)
2 mg/5 mg per mL Ophthalmic Solution (Eye Drops)White LDPE plastic bottle with nozzle and HDPE cap in 5 mL (net content) (Box of 1's)
Rx
Indoco Remedies LimitedIndia
I-Senz Medical Inc.Importer: Ambica International Corporation
DRP-7258-01
Jul 7, 2032
Zovox TBrimonidine Tartrate + Timolol (as maleate)
2 mg/5 mg per mL (0.2 %/0.5 % w/v) Ophthalmic Solution (Eye Drops)5 mL (net content) opaque white plastic bottle with nozzle and cap (box of 1 bottle)
Rx
Makcur Laboratories LimitedIndia
Ophtha Pharma Traders Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-17701-02
Feb 19, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing 0.2% brimonidine tartrate and 0.5% timolol (6.8 mg/mL timolol maleate). Ophthalmic solution: 0.2% brimonidine tartrate and 0.5% timolol. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Potential for Severe Respiratory or Cardiac Reactions (5.1)
  • Cardiac Failure (5.2)
  • Obstructive Pulmonary Disease (5.3)
  • Potentiation of Vascular Insufficiency (5.4)
  • Increased Reactivity to Allergens (5.5)
  • Potentiation of Muscle Weakness (5.6)
  • Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus (5.7)
  • Masking of Thyrotoxicosis (5.8)
  • Ocular Hypersensitivity (5.9)
5.1 Potenti

5.1 Potenti a l for Severe Respiratory or Cardiac Reactions COMBIGAN contains timolol maleate; and although administered topically can be absorbed systemically. Therefore, the same types of adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure have been reported following systemic or ophthalmic administration of timolol maleate [see Contraindications (4.1)].

Additionally, ophthalmic beta-blockers may impair compensatory tachycardia and increase risk of hypotension.

5.2 Cardiac Failure

5.2 Cardiac Failure Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure.

At the first sign or symptom of cardiac failure, COMBIGAN should be discontinued [see Contraindications (4.2)].

5.3 Obstructive Pulmonary Disease

5.3 Obstructive Pulmonary Disease Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which COMBIGAN is contraindicated [see Contraindications (4.1)] should, in general, not receive beta-blocking agents, including COMBIGAN.

5.4 Potentiation of Vascular Insufficiency

5.4 Potentiation of Vascular Insufficiency COMBIGAN may potentiate syndromes associated with vascular insufficiency. COMBIGAN should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

5.5 Increased Reactivity to Allergens

5.5 Increased Reactivity to Allergens While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

5.6 Potentiation of Muscle Weakness

5.6 Potentiation of Muscle Weakness Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.

5.7 Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus

5.7 Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

5.8 Masking of Thyrotoxicosis

5.8 Masking of Thyrotoxicosis Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

5.9 Ocular Hypersensitivity

5.9 Ocular Hypersensitivity Ocular hypersensitivity reactions have been reported with brimonidine tartrate ophthalmic solutions 0.2%, with some reported to be associated with an increase in intraocular pressure [see Contraindications (4.4)]. 5. 10 Contamination of Topical Ophthalmic Products After Use There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Do not touch the tip of the dispensing container to the eye or surrounding structures. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see Patient Counseling Information (17)]. 5.1 1 Impairment of Beta-adrenergically Mediated Reflexes During Surgery The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial.

Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia.

Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.

5.12 Contact Lens Use

5.12 Contact Lens Use COMBIGAN contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of COMBIGAN.

Drug interactions

Drug interactions (US label) US FDA label
  • 7 D RUG INTERACTIONS Antihypertensives/cardiac glycosides may lower blood pressure. (7.1)
  • Concomitant use with systemic beta-blockers may potentiate systemic beta blockade. (7.2)
  • Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (7.3)
  • Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia. (7.4)
  • Use with CNS depressants may result in an additive or potentiating effect. (7.5)
  • Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (7.6)
  • CYP2D6 inhibitors may potentiate systemic beta-blockade. (7.7)
  • Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. (7.8)
  • Monoamine oxidase inhibitors may result in increased hypotension. (7.9)
7.1 Antihypertensives/Cardiac Glycosides Because

7.1 Antihypertensives/Cardiac Glycosides Because COMBIGAN may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with COMBIGAN is advised.

7.2 Beta-adrenergic Blocking Agents

7.2 Beta-adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent either orally or intravenously and COMBIGAN should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.

7.3 Calcium Antagonists

7.3 Calcium Antagonists Caution should be used in the co-administration of beta-adrenergic blocking agents, such as COMBIGAN, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, co-administration should be avoided.

7.4 Catecholamine-depleting Drugs

7.4 Catecholamine-depleting Drugs Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

7.5 CNS Depressants

7.5 CNS Depressants Although specific drug interaction studies have not been conducted with COMBIGAN, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.

7.6 Digitalis and Calcium Antagonists

7.6 Digitalis and Calcium Antagonists The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.

7.7 CYP2D6 Inhibitors

7.7 CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.

7.8 Tricyclic Antidepressants

7.8 Tricyclic Antidepressants Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with COMBIGAN in humans can lead to resulting interference with the IOP-lowering effect. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

7.9 Monoamine Oxidase Inhibitors

7.9 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension. Caution, however, is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

( 7.6 ) CYP2D6 inhibitors may potentiate systemic beta-blockade.

Adverse reactions

Adverse reactions (US label) US FDA label
  • 6 A DVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Contraindications (4.4)] Potential for Severe Respiratory or Cardiac Reactions [see Warnings and Precautions (5.1)] Cardiac Failure [see Warnings and Precautions (5.2)] Potentiation of Vascular Insufficiency [see Warnings and Precautions (5.4)] Increased Reactivity to Allergens [see Warnings and Precautions (5.5)] Potentiation of Muscle Weakness [see Warnings and Precautions (5.6)] Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus [see Warnings and Precautions (5.7)] Masking of Thyrotoxicosis [see Warnings and Precautions (5.8)] Ocular Hypersensitivity [see Warnings and Precautions (5.9)] Contamination of Topical Ophthalmic Products after Use [see Warnings and Precautions (5.10)] Impairment of Beta-adrenergically Mediated Reflexes During Surgery [see Warnings and Precautions (5.11)] Most common adverse reactions occurring in approximately 5% to 15% of patients included allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-633-9110 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. COMBIGAN In clinical trials of 12 months duration with COMBIGAN, the most frequent reactions associated with its use occurring in approximately 5% to 15% of the patients included: allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging.

The following adverse reactions were reported in 1% to 5% of patients: asthenia, blepharitis, corneal erosion, depression, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, eyelid pruritus, foreign body sensation, headache, hypertension, oral dryness, somnolence, superficial punctate keratitis, and visual disturbance. Other adverse reactions that have been reported with the individual components are listed below.

Brimonidine Tartrate (0.1%-0.2%) Abnormal taste, allergic reaction, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival blanching, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, fatigue, flu syndrome, follicular conjunctivitis, gastrointestinal disorder, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), hordeolum, insomnia, keratitis, lid crusting, lid disorder, muscular pain, nasal dryness, ocular allergic reaction, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, superficial punctate keratopathy, tearing, upper respiratory symptoms, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity. Timolol (Ocular Administration) Body as a whole: chest pain Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, cardiac failure, cerebral ischemia, cerebral vascular accident, claudication, cold hands and feet, edema, heart block, palpitation, pulmonary edema, Raynaud’s phenomenon, syncope, and worsening of angina pectoris Digestive: anorexia, diarrhea, nausea Immunologic: Systemic lupus erythematosus Nervous System/Psychiatric: Increase in signs and symptoms of myasthenia gravis, insomnia, nightmares, paresthesia, behavioral changes and psychic disturbances including confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss Skin: Alopecia, psoriasiform rash or exacerbation of psoriasis Hypersensitivity: Signs and symptoms of systemic allergic reactions, including anaphylaxis, angioedema, urticaria, and generalized and localized rash Respiratory: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease) [see Contraindications (4.1)], dyspnea, nasal congestion, respiratory failure, upper respiratory infections Endocrine: Masked symptoms of hypoglycemia in diabetes patients [see Warnings and Precautions (5.7)] Special Senses: diplopia, choroidal detachment following filtration surgery, cystoid macular edema, decreased corneal sensitivity, pseudopemphigoid, ptosis, refractive changes, tinnitus Urogenital: Decreased libido, impotence, Peyronie’s disease, retroperitoneal fibrosis

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following reactions have been identified during postapproval use of brimonidine tartrate ophthalmic solutions, timolol ophthalmic solutions, or both in combination, in clinical practice. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Bradycardia, eyelid erythema extending to the cheek or forehead, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, rash, and vasodilation), syncope, and tachycardia. Apnea, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions [see Contraindications (4.3) and Use in Specific Populations (8.4)].

Oral Timolol/Oral Beta-blockers The following additional adverse reactions have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress Body as a whole: Decreased exercise tolerance, extremity pain, weight loss Cardiovascular: Vasodilatation, worsening of arterial insufficiency Digestive: Gastrointestinal pain, hepatomegaly, ischemic colitis, mesenteric arterial thrombosis, vomiting Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura Endocrine: Hyperglycemia, hypoglycemia; Skin: Increased pigmentation, pruritus, skin irritation, sweating Musculoskeletal: Arthralgia Nervous System/Psychiatric: An acute reversible syndrome characterized by disorientation for time and place, decreased performance on neuropsychometrics, diminished concentration, emotional lability, local weakness, reversible mental depression progressing to catatonia, slightly clouded sensorium, vertigo Respiratory: Bronchial obstruction, rales Urogenital: Urination difficulties

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with COMBIGAN in pregnant women. Limited available data from postmarketing safety reports and published literature reviews with COMBIGAN use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes (see Data).

In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Oral administration of brimonidine tartrate or timolol maleate to pregnant rats and rabbits during organogenesis at dose exposures 580 and 37 times the recommended human ophthalmic dose (RHOD) resulted in no adverse developmental effects (see Data).

Oral administration of timolol maleate to mice, rats, and rabbits during organogenesis at dose exposures up to 4,200 times the RHOD resulted in no evidence of fetal malformations (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data Limited available data from postmarketing safety reports and published literature with topical use of brimonidine ophthalmic solution in pregnant women are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes including miscarriage, stillbirth, congenital anomaly, and events experienced by the breastfed infant.

Animal Data Embryofetal development studies were conducted with oral administration of brimonidine tartrate during organogenesis in rats (gestation days 6 to 15) and rabbits (gestation days 6 to 18). No adverse developmental effects were observed in rats up to 2.5 mg/kg/day and rabbits up to 5 mg/kg/day. These doses represent exposures 580 and 37 times higher, respectively, than the recommended human ophthalmic dose (RHOD) of COMBIGAN at 1 drop in both eyes twice daily.

Orally administered brimonidine crossed the placenta in pregnant rats and entered the fetal circulation to a limited extent. Embryofetal development studies conducted with timolol during organogenesis in mice, rats, and rabbits at oral doses up to 50 mg/kg/day [4,200 times the maximum recommended human ophthalmic dose of 0.012 mg/kg/day on a mg/kg basis (MRHOD)] demonstrated no evidence of fetal malformations.

Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1,000 mg/kg/day (83,000 times the MRHOD) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses 8,300 times the MRHOD without apparent maternotoxicity.

Mechanism of action

12.1 Mechanism of Action COMBIGAN is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.

The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. COMBIGAN is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate is a beta 1 and beta 2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion In the crossover study in healthy volunteers, the plasma concentration of brimonidine declined with a systemic half-life of approximately 3 hours.

The apparent systemic half-life of timolol was about 7 hours after ocular administration.

Urinary excretion is the major route of elimination of brimonidine and its metabolites.

Unchanged timolol and its metabolites are excreted by the kidney.

Following oral administration of timolol maleate, the plasma half-life of timolol is essentially unchanged in patients with moderate renal insufficiency.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Systemic absorption of brimonidine and timolol was assessed in healthy volunteers and patients following topical dosing with COMBIGAN. Normal volunteers dosed with one drop of COMBIGAN twice daily in both eyes for seven days showed peak plasma brimonidine and timolol concentrations of 30 pg/mL and 400 pg/mL, respectively.

Plasma concentrations of brimonidine peaked at 1 to 4 hours after ocular dosing. Peak plasma concentrations of timolol occurred approximately 1 to 3 hours post-dose. In a crossover study of COMBIGAN, brimonidine tartrate 0.2%, and timolol 0.5% administered twice daily for 7 days in healthy volunteers, the mean brimonidine area-under-the-plasma-concentration-time curve (AUC) for COMBIGAN was 128 ± 61 pg•hr/mL versus 141 ± 106 pg•hr/mL for the respective monotherapy treatments; mean C max values of brimonidine were comparable following COMBIGAN treatment versus monotherapy (32.7 ± 15 pg/mL versus 34.7 ± 22.6 pg/mL, respectively).

Mean timolol AUC for COMBIGAN was similar to that of the respective monotherapy treatment (2919 ± 1679 pg•hr/mL versus 2909 ± 1231 pg•hr/mL, respectively); mean C max of timolol was approximately 20% lower following COMBIGAN treatment versus monotherapy. In a parallel study in patients dosed twice daily with COMBIGAN, twice daily with timolol 0.5%, or three times daily with brimonidine tartrate 0.2%, one-hour post dose plasma concentrations of timolol and brimonidine were approximately 30-40% lower with COMBIGAN than their respective monotherapy values.

The lower plasma brimonidine concentrations with COMBIGAN appears to be due to twice-daily dosing for COMBIGAN versus three-times dosing with brimonidine tartrate 0.2%. Distribution The protein binding of timolol is approximately 60%. The protein binding of brimonidine is approximately 29%. Elimination Metabolism In humans, brimonidine is extensively metabolized by the liver.

Timolol is partially metabolized by the liver. Excretion In the crossover study in healthy volunteers, the plasma concentration of brimonidine declined with a systemic half-life of approximately 3 hours. The apparent systemic half-life of timolol was about 7 hours after ocular administration. Urinary excretion is the major route of elimination of brimonidine and its metabolites.

Approximately 87% of an orally-administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine. Unchanged timolol and its metabolites are excreted by the kidney. Special Populations Patients with Renal Impairment COMBIGAN has not been studied in patients with renal impairment. A study of patients with renal failure showed that timolol was not readily removed by dialysis.

The effect of dialysis on brimonidine pharmacokinetics in patients with renal failure is not known. Following oral administration of timolol maleate, the plasma half-life of timolol is essentially unchanged in patients with moderate renal insufficiency. Patients with Hepatic Impairment COMBIGAN has not been studied in patients with hepatic impairment.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. COMBIGAN · Allergan, Inc. [US FDA-approved label, version 22, March 17, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .